Newronika was founded on a simple conviction: adaptive therapy should be the standard, not the exception.
Newronika is a spin-off of two of Italy’s leading research institutions, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan. Based on two decades of work, we’re building αDBS technology that learns from the brain in real time, advancing neuromodulation for patients and clinicians worldwide.
Our leadership team and scientific advisory board represent decades of clinical and engineering expertise across DBS, neural bioengineering, medical informatics, and movement disorders.
The same adaptive DBS technology that works in Parkinson's is being studied across a spectrum of brain disorders; there are dozens of indications that could be addressed with aDBS.
We have identified numerous investigational and emerging opportunities in indications that we will investigate in clinical trials.
Partner with Newronika to bring the next generation of adaptive brain therapy to patients who need it most.
Whether you’re a clinician, researcher, investor, or partner — we’d love to hear from you.
